Clinical trials: Philadelphia Positive Acute Lymphoblastic Leukemia
- Condition Philadelphia Positive Acute Lymphoblastic Leukemia
- Funder type Industry (pharma, biotech, devices)
Chronic Myeloid Leukemia, Leukemia, Lymphoblastic, Acute, Philadelphia-positive
Dasatinib (BMS-354825) in Subjects With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
The purpose of this clinical research study is to learn if BMS-354825 will have activity as defined by hematologic responses in subjects with lymphoid blast phase chronic myeloid leukemia (CML) and Philadelphia chromosome…
- Trial name
- NCT00101595
- Testing
- Dasatinib
- Where
- 60 sites in United States, Argentina and 18 more
- Volunteers
- 96 people
- Sponsor
- Bristol-Myers Squibb
Philadelphia Positive, BCR-ABL Positive
Phase II Front-line Ponatinib in Adult Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.
Drug resistance resulting from emergence of Imatinib-resistant BCR-ABL clones is a significant problem in Ph positive ALL patients because after a very good initial response to one TKI inhibitor, many patients relapse within one…
- Conditions
- Philadelphia Positive, BCR-ABL Positive, Acute Lymphoblastic Leukemia
- Trial name
- LAL1811 (NCT01641107)
- Testing
- Ponatinib
- Where
- 42 sites in Italy
- Volunteers
- 44 people
- Sponsor
- Incyte Corporation
Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia
Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)
This study will investigate if nilotinib provides an improved safety and efficacy profile over that seen in patients receiving Imatinib.
- Trial name
- NCT01279473
- Testing
- Nilotinib
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST)
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
The purpose of this study was to allow continued use of nilotinib in patients who were on nilotinib treatment in a Novartis-sponsored, Oncology Clinical Development \& Medical Affairs (CD\&MA) study and were benefiting from the…
- Conditions
- Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST), Acute Lymphoblastic Leukemia (ALL), Receptor Tyrosine Kinase (KIT) Mutated Melanoma
- Trial name
- NCT01735955
- Testing
- Nilotinib
- Where
- 33 sites in United States, Austria and 14 more
- Volunteers
- 57 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Myelogenous Leukemia, Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL
The design of a phase I, open label, dose finding study was chosen in order to establish a safe and tolerated dose of single agent ABL001 in Chronic myeloid leukemia (CML) and Philadelphia chromosome positive Acute lymphoblastic…
- Trial name
- NCT02081378
- Testing
- Asciminib (ABL001), Nilotinib, Imatinib
- Where
- 18 sites in United States, Australia and 8 more
- Volunteers
- 326 people
- Sponsor
- Novartis Pharmaceuticals
Philadelphia Positive Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia
The objectives of Part 1 of the study were: To determine the rate of hematologic response (HR) lasting ≥4 weeks in participants with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the accelerated phase…
- Conditions
- Philadelphia Positive Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
- Trial name
- NCT00171249
- Testing
- STI571 400 mg, STI571 600 mg
- Where
- 12 sites in United States, France and 3 more
- Volunteers
- 293 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia
Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study
To determine the long term safety and tolerability of dasatinib exposure in subjects previously treated in CA180-002.
- Trial name
- NCT00978731
- Testing
- Dasatinib
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
Leukemia, Pediatric
Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
The purpose of this study is to determine whether Dasatinib when added to standard chemotherapy is effective and safe in the treatment of pediatric philadelphia chromosome positive acute lymphoblastic leukemia
- Trial name
- NCT01460160
- Testing
- Dasatinib
- Where
- 128 sites in United States, Australia and 4 more
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia
The objective of this study is to determine the efficacy and safety of imatinib mesylate in patients diagnosed as having Philadelphia chromosome positive acute lymphocytic leukemia (ALL).
- Trial name
- NCT00154349
- Testing
- Imatinib Mesylate
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals